Newsfiscal.ai
Eikon Therapeutics Presents Updated Clinical Data for EIK1001 at ESMO 2026
· Published
Article summary
Eikon Therapeutics announced updated clinical results for its TLR7/8 dual-agonist EIK1001 in combination with pembrolizumab and chemotherapy for the treatment of stage 4 non-small cell lung cancer.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…